As of May, 8 Inogen, Inc. (INGN) EPS Estimated At $0.27

April 16, 2018 - By Joseph March

Inogen, Inc. (NASDAQ:INGN) Corporate Logo
Big Money Sentiment decreased to 1.18 in 2017 Q4. It has change of 0.02, from 2017Q3’s 1.2. The ratio dropped due to Inogen, Inc. positioning: 19 sold and 68 reduced. 37 funds acquired stakes and 66 increased stakes. Investors holded 20.61 million in 2017Q3 but now own 20.27 million shares or 1.65% less.
Laurion Cap Management Lp has invested 0% of its capital in Inogen, Inc. (NASDAQ:INGN). Pinebridge Invests L P accumulated 6,295 shs or 0.02% of the stock. Bancorp Of Montreal Can stated it has 16,450 shs. Pnc Fin Services accumulated 794 shs or 0% of the stock. Thrivent For Lutherans accumulated 136,328 shs. Ameritas Inv Prtnrs Incorporated owns 1,495 shs for 0.01% of their capital. Axiom Ltd Liability Corporation De holds 48,845 shs. Bamco Incorporated Ny reported 0.01% stake. Lenox Wealth Advisors Inc holds 837 shs. Thornburg Inv Mgmt Incorporated accumulated 53,354 shs. Bogle Invest Mgmt Lp De holds 0.17% or 19,102 shs. C M Bidwell And Limited stated it has 0.25% of its capital in Inogen, Inc. (NASDAQ:INGN). Northwestern Mutual Wealth Mgmt Co, a Wisconsin-based fund reported 17 shs. Rockefeller Ser invested in 301,499 shs or 0.57% of the stock. Tci Wealth Advsr has 0% invested in Inogen, Inc. (NASDAQ:INGN) for 21 shs.

Investors wait Inogen, Inc. (NASDAQ:INGN)’s quarterly earnings on May, 8., as reported by RTT. Last year’s earnings per share was $0.27, while now analysts expect change of 0.00 % from current $0.27 earnings per share. If INGN’s EPS is $0.27 the profit will hit $5.73 million for 129.10 P/E. After $0.31 earnings per share was revealed last quarter, analysts now see negative EPS growth of -12.90 % for Inogen, Inc.. The stock increased 0.37% or $0.51 during the last trading session, reaching $139.43.Inogen, Inc. is uptrending after having risen 59.63% since April 17, 2017. INGN has 159,159 volume or 16.34% up from normal. The stock outperformed the S&P 500 by 48.08%.

Inogen, Inc. (NASDAQ:INGN) Ratings Coverage

Total analysts of 4 have positions in Inogen (NASDAQ:INGN) as follows: 4 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 8, 2017 according to StockzIntelligence Inc Inogen has 6 analyst reports. On Tuesday, February 20 PiperJaffray upgraded the shares of INGN in report to “Overweight” rating. On Wednesday, February 28 the firm earned “Buy” rating by Needham. On Wednesday, November 8 the stock of Inogen, Inc. (NASDAQ:INGN) earned “Buy” rating by Needham. On Tuesday, February 20 the rating was upgraded by Piper Jaffray to “Buy”. In Wednesday, November 8 report Leerink Swann maintained it with “Buy” rating and $120.0 target. On Friday, April 13 the stock of Inogen, Inc. (NASDAQ:INGN) has “Buy” rating given by Needham.

Inogen, Inc., a medical technology company, primarily develops, makes, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally.The firm is valued at $2.96 billion. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.The P/E ratio is 145.24. It offers Inogen One systems, which are portable devices that concentrate the air around the patients to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories.

Inogen, Inc. (NASDAQ:INGN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.